NCT05963087View on ClinicalTrials.gov

Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Colorectal Cancer
Interventions
DRUG

Cetuximab Dabrafenib Tislelizumab

Dabrafenib 150mg，BID, Cetuximab 250mg/m2, Tislelizumab 200mg Treatment every three weeks

Trial Locations (1)

Unknown

Zhejiang Cancer Institute & Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER

NCT05963087 - Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter